| A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | Drug or Drug Combo | Animal Model | Tumor Type | Prinicpal Investigator | Prinicpal Investigator's Email | Additional Contact Person | Additional Contact Person | |||||||||||||||||
2 | Ceritinib | Larval Zebrafish | Neuroblastoma, ALCL | Jason Berman | jberman@cheo.on.ca | Nadine Azzam | NAzzam@cheo.on.ca | |||||||||||||||||
3 | Crizotinib | Larval Zebrafish | Neuroblastoma | Jason Berman | jberman@cheo.on.ca | Nadine Azzam | NAzzam@cheo.on.ca | |||||||||||||||||
4 | Lorlatinib | Larval Zebrafish | Neuroblastoma | Jason Berman | jberman@cheo.on.ca | Nadine Azzam | NAzzam@cheo.on.ca | |||||||||||||||||
5 | Tazemetostat | Larval Zebrafish | Ewing Sarcoma, Melanotic Schwannoma | Jason Berman | jberman@cheo.on.ca | Nadine Azzam | NAzzam@cheo.on.ca | |||||||||||||||||
6 | Temsirolimus | Larval Zebrafish | Ewing Sarcoma | Jason Berman | jberman@cheo.on.ca | Nadine Azzam | NAzzam@cheo.on.ca | |||||||||||||||||
7 | Gemcitabine | Larval Zebrafish | Ewing Sarcoma, Melanotic Schwannoma | Jason Berman | jberman@cheo.on.ca | Nadine Azzam | NAzzam@cheo.on.ca | |||||||||||||||||
8 | Gefitinib | Larval Zebrafish | Ewing Sarcoma | Jason Berman | jberman@cheo.on.ca | Nadine Azzam | NAzzam@cheo.on.ca | |||||||||||||||||
9 | Venetoclax | Larval Zebrafish | Neuroblastoma | Jason Berman | jberman@cheo.on.ca | Nadine Azzam | NAzzam@cheo.on.ca | |||||||||||||||||
10 | Afuresertib | Larval Zebrafish | Ewing Sarcoma | Jason Berman | jberman@cheo.on.ca | Nadine Azzam | NAzzam@cheo.on.ca | |||||||||||||||||
11 | Alectinib | Larval Zebrafish | Neuroblastoma, ALCL | Jason Berman | jberman@cheo.on.ca | Nadine Azzam | NAzzam@cheo.on.ca | |||||||||||||||||
12 | Imatinib | Larval Zebrafish | Melanotic Schwannoma, CML | Jason Berman | jberman@cheo.on.ca | Nadine Azzam | NAzzam@cheo.on.ca | |||||||||||||||||
13 | Cisplatin | Larval Zebrafish | Melanotic Schwannoma, Neuroblastoma | Jason Berman | jberman@cheo.on.ca | Nadine Azzam | NAzzam@cheo.on.ca | |||||||||||||||||
14 | Cetuximab | Larval Zebrafish | Spitzoid Melanoma | Jason Berman | jberman@cheo.on.ca | Nadine Azzam | NAzzam@cheo.on.ca | |||||||||||||||||
15 | Cetuximab + Irinotecan | Larval Zebrafish | Spitzoid Melanoma | Jason Berman | jberman@cheo.on.ca | Nadine Azzam | NAzzam@cheo.on.ca | |||||||||||||||||
16 | Irinotecan + Temozolomide | Larval Zebrafish | Ewing Sarcoma, Melanotic Schwannoma | Jason Berman | jberman@cheo.on.ca | Nadine Azzam | NAzzam@cheo.on.ca | |||||||||||||||||
17 | Irinotecan + Temozolomide + Temsirolimus | Larval Zebrafish | Ewing Sarcoma | Jason Berman | jberman@cheo.on.ca | Nadine Azzam | NAzzam@cheo.on.ca | |||||||||||||||||
18 | Gefitinib + Gemcitabine | Larval Zebrafish | Ewing Sarcoma | Jason Berman | jberman@cheo.on.ca | Nadine Azzam | NAzzam@cheo.on.ca | |||||||||||||||||
19 | Gefintinb + Temozolomide | Larval Zebrafish | Ewing Sarcoma | Jason Berman | jberman@cheo.on.ca | Nadine Azzam | NAzzam@cheo.on.ca | |||||||||||||||||
20 | Cyclophospamide + Topotecan | Larval Zebrafish | Neuroblastoma, Melanotic Schwannoma | Jason Berman | jberman@cheo.on.ca | Nadine Azzam | NAzzam@cheo.on.ca | |||||||||||||||||
21 | Cyclophospamide + Topotecan + Crizotinib | Larval Zebrafish | Neuroblastoma | Jason Berman | jberman@cheo.on.ca | Nadine Azzam | NAzzam@cheo.on.ca | |||||||||||||||||
22 | Cyclophospamide + Topotecan + Ceritinib | Larval Zebrafish | Neuroblastoma | Jason Berman | jberman@cheo.on.ca | Nadine Azzam | NAzzam@cheo.on.ca | |||||||||||||||||
23 | Cyclophospamide + Topotecan + Venetoclax | Larval Zebrafish | Neuroblastoma | Jason Berman | jberman@cheo.on.ca | Nadine Azzam | NAzzam@cheo.on.ca | |||||||||||||||||
24 | Lenvatinib | Larval Zebrafish | Ewing Sarcoma | Jason Berman | jberman@cheo.on.ca | Nadine Azzam | NAzzam@cheo.on.ca | |||||||||||||||||
25 | Talazoparib | Larval Zebrafish | Ewing Sarcoma | Jason Berman | jberman@cheo.on.ca | Nadine Azzam | NAzzam@cheo.on.ca | |||||||||||||||||
26 | Talazoparib + Irinotecan | Larval Zebrafish | Ewing Sarcoma | Jason Berman | jberman@cheo.on.ca | Nadine Azzam | NAzzam@cheo.on.ca | |||||||||||||||||
27 | Cabozantinib | Larval Zebrafish | Ewing Sarcoma | Jason Berman | jberman@cheo.on.ca | Nadine Azzam | NAzzam@cheo.on.ca | |||||||||||||||||
28 | Cyclophosphamide + Topotecan + Cabozantinib | Larval Zebrafish | Ewing Sarcoma | Jason Berman | jberman@cheo.on.ca | Nadine Azzam | NAzzam@cheo.on.ca | |||||||||||||||||
29 | Paxalisib | Larval Zebrafish | Ewing Sarcoma | Jason Berman | jberman@cheo.on.ca | Nadine Azzam | NAzzam@cheo.on.ca | |||||||||||||||||
30 | Irinotecan + Temozolomide + alisertib | Larval Zebrafish | Neuroblastoma | Jason Berman | jberman@cheo.on.ca | Nadine Azzam | NAzzam@cheo.on.ca | |||||||||||||||||
31 | Volasertib | Larval Zebrafish | Neuroblastoma | Jason Berman | jberman@cheo.on.ca | Nadine Azzam | NAzzam@cheo.on.ca | |||||||||||||||||
32 | Pazopanib | Larval Zebrafish | Undifferentiated Sarcoma | Jason Berman | jberman@cheo.on.ca | Nadine Azzam | NAzzam@cheo.on.ca | |||||||||||||||||
33 | Ifosfamide + Etoposide | Larval Zebrafish | Undifferentiated Sarcoma | Jason Berman | jberman@cheo.on.ca | Nadine Azzam | NAzzam@cheo.on.ca | |||||||||||||||||
34 | Ifosfamide + Etoposide + Lenvatinib | Larval Zebrafish | Undifferentiated Sarcoma | Jason Berman | jberman@cheo.on.ca | Nadine Azzam | NAzzam@cheo.on.ca | |||||||||||||||||
35 | Irinotecan + Temozolomide + Talazoparib | Larval Zebrafish | Osteosarcoma | Jason Berman | jberman@cheo.on.ca | Nadine Azzam | NAzzam@cheo.on.ca | |||||||||||||||||
36 | Palbociclib | Larval Zebrafish | Rhabdomyosarcoma fusion positive | Jason Berman | jberman@cheo.on.ca | Nadine Azzam | NAzzam@cheo.on.ca | |||||||||||||||||
37 | Ponatinib | Larval Zebrafish | Rhabdomyosarcoma fusion positive | Jason Berman | jberman@cheo.on.ca | Nadine Azzam | NAzzam@cheo.on.ca | |||||||||||||||||
38 | Palbociclib + Temsirolimus | Larval Zebrafish | Rhabdomyosarcoma fusion positive | Jason Berman | jberman@cheo.on.ca | Nadine Azzam | NAzzam@cheo.on.ca | |||||||||||||||||
39 | Temsirolimus + Vinorelbine + Cyclophosphamide | Larval Zebrafish | Rhabdomyosarcoma fusion negative | Jason Berman | jberman@cheo.on.ca | Nadine Azzam | NAzzam@cheo.on.ca | |||||||||||||||||
40 | Dasatinib | Larval Zebrafish | ALL | Jason Berman | jberman@cheo.on.ca | Nadine Azzam | NAzzam@cheo.on.ca | |||||||||||||||||
41 | Olaparib + Temsirolimus | Larval Zebrafish | Ewing sarcoma | Jason Berman | jberman@cheo.on.ca | Nadine Azzam | NAzzam@cheo.on.ca | |||||||||||||||||
42 | Regorafenib | Larval Zebrafish | Gastrointestinal stromal tumour | Jason Berman | jberman@cheo.on.ca | Nadine Azzam | NAzzam@cheo.on.ca | |||||||||||||||||
43 | Rapamycin | Larval Zebrafish | LAM | Jason Berman | jberman@cheo.on.ca | Nadine Azzam | NAzzam@cheo.on.ca | |||||||||||||||||
44 | Doxorubicin | Larval Zebrafish | T-ALL | Jason Berman | jberman@cheo.on.ca | Nadine Azzam | NAzzam@cheo.on.ca | |||||||||||||||||
45 | Daunorubicin | Larval Zebrafish | AML | Jason Berman | jberman@cheo.on.ca | Nadine Azzam | NAzzam@cheo.on.ca | |||||||||||||||||
46 | Vincristine | Mouse (Model M25FV24c) | RMS | Rebecca Gladdy | gladdy@lunenfeld.ca | Yael Babichev | babichev@lunenfeld.ca | |||||||||||||||||
47 | GSK2126458 | Mouse (Model M25FV24c) | RMS | Rebecca Gladdy | gladdy@lunenfeld.ca | Yael Babichev | babichev@lunenfeld.ca | |||||||||||||||||
48 | Vincristine + GSK2126458 | Mouse (Model M25FV24c) | RMS | Rebecca Gladdy | gladdy@lunenfeld.ca | Yael Babichev | babichev@lunenfeld.ca | |||||||||||||||||
49 | BEZ235 | Mouse (Model STS39 xenograft) | LMS | Rebecca Gladdy | gladdy@lunenfeld.ca | Yael Babichev | babichev@lunenfeld.ca | |||||||||||||||||
50 | Doxorubicin | Mouse (Model STS39 xenograft) | LMS | Rebecca Gladdy | gladdy@lunenfeld.ca | Yael Babichev | babichev@lunenfeld.ca | |||||||||||||||||
51 | Doxorubicin + BEZ235 | Mouse (Model STS39 xenograft) | LMS | Rebecca Gladdy | gladdy@lunenfeld.ca | Yael Babichev | babichev@lunenfeld.ca | |||||||||||||||||
52 | BEZ235 | Mouse (Model SKLMS 1 xenograft) | LMS | Rebecca Gladdy | gladdy@lunenfeld.ca | Yael Babichev | babichev@lunenfeld.ca | |||||||||||||||||
53 | Doxorubicin | Mouse (Model SKLMS 1 xenograft) | LMS | Rebecca Gladdy | gladdy@lunenfeld.ca | Yael Babichev | babichev@lunenfeld.ca | |||||||||||||||||
54 | Doxorubicin + BEZ235 | Mouse (Model SKLMS 1 xenograft) | LMS | Rebecca Gladdy | gladdy@lunenfeld.ca | Yael Babichev | babichev@lunenfeld.ca | |||||||||||||||||
55 | Simvastatin | Mouse (Model STS 148 xenograft) | UPS | Rebecca Gladdy | gladdy@lunenfeld.ca | Yael Babichev | babichev@lunenfeld.ca | |||||||||||||||||
56 | Doxorubicin | Mouse (Model STS 148 xenograft) | UPS | Rebecca Gladdy | gladdy@lunenfeld.ca | Yael Babichev | babichev@lunenfeld.ca | |||||||||||||||||
57 | Doxorubicin + Simvastatin | Mouse (Model STS 148 xenograft) | UPS | Rebecca Gladdy | gladdy@lunenfeld.ca | Yael Babichev | babichev@lunenfeld.ca | |||||||||||||||||
58 | Simvastatin | Mouse (Model STS39 xenograft) | LMS | Rebecca Gladdy | gladdy@lunenfeld.ca | Yael Babichev | babichev@lunenfeld.ca | |||||||||||||||||
59 | Doxorubicin | Mouse (Model STS39 xenograft) | LMS | Rebecca Gladdy | gladdy@lunenfeld.ca | Yael Babichev | babichev@lunenfeld.ca | |||||||||||||||||
60 | Doxorubicin + Simvastatin | Mouse (Model STS39 xenograft) | LMS | Rebecca Gladdy | gladdy@lunenfeld.ca | Yael Babichev | babichev@lunenfeld.ca | |||||||||||||||||
61 | Olaparib | Adult Zebrafish | Madline Hayes | madeline.hayes@sickkids.ca | ||||||||||||||||||||
62 | Temozolomide | Adult Zebrafish | Madline Hayes | madeline.hayes@sickkids.ca | ||||||||||||||||||||
63 | Olaparib & Temozolomide | Adult Zebrafish | Madline Hayes | madeline.hayes@sickkids.ca | ||||||||||||||||||||
64 | Cyclophosphamide + Dexamethasone | Mouse | Gregor Reid | grogreid@mail.ubc.ca | ||||||||||||||||||||
65 | Olaparib | Mouse | Gregor Reid | grogreid@mail.ubc.ca | ||||||||||||||||||||
66 | Dexamethasone | Mouse | Subdermal, Leukemia, Brain | Donna Senger | senger@ucalgary.ca | Jennifer Chan | jawchan@ucalgary.ca | |||||||||||||||||
67 | Cyclophosphamide | Mouse | Subdermal, Leukemia, Brain | Donna Senger | senger@ucalgary.ca | Jennifer Chan | jawchan@ucalgary.ca | |||||||||||||||||
68 | Temozolomide | Mouse | Subdermal, Leukemia, Brain | Donna Senger | senger@ucalgary.ca | Jennifer Chan | jawchan@ucalgary.ca | |||||||||||||||||
69 | Proteasome Inhibitors (Bortezomib, Carfilzomib, Disulfiram/Cu+) | Mouse | Subdermal, Leukemia, Brain | Donna Senger | senger@ucalgary.ca | Jennifer Chan | jawchan@ucalgary.ca | |||||||||||||||||
70 | PARP inhibitor (ABT888, Olaparib) | Mouse | Subdermal, Leukemia, Brain | Donna Senger | senger@ucalgary.ca | Jennifer Chan | jawchan@ucalgary.ca | |||||||||||||||||
71 | HDAC Inhibitor | Mouse | Subdermal, Leukemia, Brain | Donna Senger | senger@ucalgary.ca | Jennifer Chan | jawchan@ucalgary.ca | |||||||||||||||||
72 | Kinase inhibitors (Ponatinib, AZD9291, AZD8186) | Mouse | Subdermal, Leukemia, Brain | Donna Senger | senger@ucalgary.ca | Jennifer Chan | jawchan@ucalgary.ca | |||||||||||||||||
73 | Checkpoint Inhibitor (Ly2603618) | Mouse | Subdermal, Leukemia, Brain | Donna Senger | senger@ucalgary.ca | Jennifer Chan | jawchan@ucalgary.ca | |||||||||||||||||
74 | Niclosamide | Mouse | Subdermal, Leukemia, Brain | Donna Senger | senger@ucalgary.ca | Jennifer Chan | jawchan@ucalgary.ca | |||||||||||||||||
75 | Montelukast | Mouse | Subdermal, Leukemia, Brain | Donna Senger | senger@ucalgary.ca | Jennifer Chan | jawchan@ucalgary.ca | |||||||||||||||||
76 | Bromodomain inhibitor (OTX015) | Mouse | Subdermal, Leukemia, Brain | Donna Senger | senger@ucalgary.ca | Jennifer Chan | jawchan@ucalgary.ca | |||||||||||||||||
77 | Clioquinol | Mouse | Subdermal, Leukemia, Brain | Donna Senger | senger@ucalgary.ca | Jennifer Chan | jawchan@ucalgary.ca | |||||||||||||||||
78 | Aurora Kinase Inhibition | Donna Senger | senger@ucalgary.ca | Jennifer Chan | jawchan@ucalgary.ca | |||||||||||||||||||
79 | ZM 447439 | Cell Lines | Donna Senger | senger@ucalgary.ca | Jennifer Chan | jawchan@ucalgary.ca | ||||||||||||||||||
80 | VX-680 | Cell Lines | Donna Senger | senger@ucalgary.ca | Jennifer Chan | jawchan@ucalgary.ca | ||||||||||||||||||
81 | AZD1152 | Cell Lines | Donna Senger | senger@ucalgary.ca | Jennifer Chan | jawchan@ucalgary.ca | ||||||||||||||||||
82 | HER2/EGF-R Inhibition | Donna Senger | senger@ucalgary.ca | Jennifer Chan | jawchan@ucalgary.ca | |||||||||||||||||||
83 | Lapatinib | Cell Lines | Donna Senger | senger@ucalgary.ca | Jennifer Chan | jawchan@ucalgary.ca | ||||||||||||||||||
84 | Canertinib (CI-1033) | Cell Lines | Donna Senger | senger@ucalgary.ca | Jennifer Chan | jawchan@ucalgary.ca | ||||||||||||||||||
85 | BIBW 2992 (Tovok) | Cell Lines | Donna Senger | senger@ucalgary.ca | Jennifer Chan | jawchan@ucalgary.ca | ||||||||||||||||||
86 | BMS-599626 | Cell Lines | Donna Senger | senger@ucalgary.ca | Jennifer Chan | jawchan@ucalgary.ca | ||||||||||||||||||
87 | Gefitinib (Iressa) | Cell Lines | Donna Senger | senger@ucalgary.ca | Jennifer Chan | jawchan@ucalgary.ca | ||||||||||||||||||
88 | Erlotinib, Hydrochloride | Cell Lines | Donna Senger | senger@ucalgary.ca | Jennifer Chan | jawchan@ucalgary.ca | ||||||||||||||||||
89 | CUDC-101 | Cell Lines | Donna Senger | senger@ucalgary.ca | Jennifer Chan | jawchan@ucalgary.ca | ||||||||||||||||||
90 | WZ4002 | Cell Lines | Donna Senger | senger@ucalgary.ca | Jennifer Chan | jawchan@ucalgary.ca | ||||||||||||||||||
91 | Dacomitinib | Cell Lines | Donna Senger | senger@ucalgary.ca | Jennifer Chan | jawchan@ucalgary.ca | ||||||||||||||||||
92 | mTOR Inhibition | Donna Senger | senger@ucalgary.ca | Jennifer Chan | jawchan@ucalgary.ca | |||||||||||||||||||
93 | Pp242 | Cell Lines | Donna Senger | senger@ucalgary.ca | Jennifer Chan | jawchan@ucalgary.ca | ||||||||||||||||||
94 | Rapamycin (Sirolimus) | Cell Lines | Donna Senger | senger@ucalgary.ca | Jennifer Chan | jawchan@ucalgary.ca | ||||||||||||||||||
95 | AZD8055 | Cell Lines | Donna Senger | senger@ucalgary.ca | Jennifer Chan | jawchan@ucalgary.ca | ||||||||||||||||||
96 | INK128 | Cell Lines | Donna Senger | senger@ucalgary.ca | Jennifer Chan | jawchan@ucalgary.ca | ||||||||||||||||||
97 | OSI-027 | Cell Lines | Donna Senger | senger@ucalgary.ca | Jennifer Chan | jawchan@ucalgary.ca | ||||||||||||||||||
98 | PF-04691502 | Cell Lines | Donna Senger | senger@ucalgary.ca | Jennifer Chan | jawchan@ucalgary.ca | ||||||||||||||||||
99 | GDC-0980 | Cell Lines | Donna Senger | senger@ucalgary.ca | Jennifer Chan | jawchan@ucalgary.ca | ||||||||||||||||||
100 | Deforolimus | Cell Lines | Donna Senger | senger@ucalgary.ca | Jennifer Chan | jawchan@ucalgary.ca |